[go: up one dir, main page]

MX2009009156A - Mejora de la produccion de proteina. - Google Patents

Mejora de la produccion de proteina.

Info

Publication number
MX2009009156A
MX2009009156A MX2009009156A MX2009009156A MX2009009156A MX 2009009156 A MX2009009156 A MX 2009009156A MX 2009009156 A MX2009009156 A MX 2009009156A MX 2009009156 A MX2009009156 A MX 2009009156A MX 2009009156 A MX2009009156 A MX 2009009156A
Authority
MX
Mexico
Prior art keywords
pkd
cert
protein production
reduces
transport
Prior art date
Application number
MX2009009156A
Other languages
English (en)
Inventor
Hitto Kaufmann
Lore Florin
Eric Becker
Monilola Olayioye
Angelika Hausser
Tim Fugmann
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP07103406A external-priority patent/EP1964922A1/en
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of MX2009009156A publication Critical patent/MX2009009156A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)

Abstract

La invención se refiere al campo de la producción de proteína y a la tecnología de cultivo celular. Se identifica la CERT como un sustrato novedoso in vivo de PKD. La fosforilación en la serina 132 por PKD reduce la afinidad de CERT hacia su diana lipídica 4-fosfato de fosfatidilinosiol en las membranas de Golgi y reduce la actividad de transferencia de ceramida, identificando a PKD como un regulador de la homeostasis lipídica. La presente invención muestra que la CERT es a su vez crítica para al activación de PKD y el transporte de carga de proteína dependiente de PKD a la membrana plasmática. La interdependencia de PKD y CERT es por tanto clave para el mantenimiento de la integridad de la membrana de Golgi y el transporte secretor.
MX2009009156A 2007-03-02 2008-02-29 Mejora de la produccion de proteina. MX2009009156A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP07103406A EP1964922A1 (en) 2007-03-02 2007-03-02 Improvement of protein production
EP07104226 2007-03-15
EP07116358 2007-09-13
PCT/EP2008/052493 WO2008107388A1 (en) 2007-03-02 2008-02-29 Improvement of protein production

Publications (1)

Publication Number Publication Date
MX2009009156A true MX2009009156A (es) 2009-09-04

Family

ID=39639553

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009009156A MX2009009156A (es) 2007-03-02 2008-02-29 Mejora de la produccion de proteina.

Country Status (23)

Country Link
US (4) US20130177919A1 (es)
EP (3) EP2522729A1 (es)
JP (1) JP5467415B2 (es)
KR (1) KR20100015363A (es)
AR (2) AR065573A1 (es)
AU (1) AU2008223874B2 (es)
BR (1) BRPI0808542A2 (es)
CA (1) CA2677925A1 (es)
CY (1) CY1113710T1 (es)
DK (1) DK2126093T3 (es)
EA (1) EA018190B1 (es)
ES (1) ES2397274T3 (es)
HR (1) HRP20121077T1 (es)
IL (1) IL200030A0 (es)
MX (1) MX2009009156A (es)
MY (1) MY148472A (es)
NZ (1) NZ580043A (es)
PL (1) PL2126093T3 (es)
PT (1) PT2126093E (es)
SG (1) SG182160A1 (es)
SI (1) SI2126093T1 (es)
TW (1) TWI419902B (es)
WO (1) WO2008107388A1 (es)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008107388A1 (en) 2007-03-02 2008-09-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Improvement of protein production
WO2010029101A1 (de) * 2008-09-10 2010-03-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung hsa-produzierender zellen
US9340592B2 (en) 2009-05-05 2016-05-17 Boehringer Ingelheim International Gmbh CHO/CERT cell lines
US20120190065A1 (en) * 2009-05-15 2012-07-26 Boehringer Ingelheim International Gmbh Combinatorial engineering
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DE19177059T1 (de) 2010-10-01 2021-10-07 Modernatx, Inc. N1-methyl-pseudouracile enthältendes ribonucleinsäuren sowie ihre verwendungen
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
US8506797B2 (en) * 2011-04-10 2013-08-13 Therapeutic Proteins International, LLC Downstream bioprocessing device
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
HUE057725T2 (hu) 2011-10-03 2022-06-28 Modernatx Inc Módosított nukleozidok, nukleotidok és nukleinsavak és ezek felhasználása
LT2771031T (lt) 2011-10-28 2018-08-27 Prothena Biosciences Limited Humanizuoti antikūnai, kurie atpažįsta alfa sinukleiną
US8852435B2 (en) * 2011-11-29 2014-10-07 Therapeutics Proteins International, LLC Purification and separation treatment assembly (PASTA) for biological products
HRP20220717T1 (hr) 2011-12-16 2022-07-22 Modernatx, Inc. Modificirani pripravci mrna
MX360778B (es) 2012-01-27 2018-11-16 Prothena Biosciences Ltd Anticuerpos humanizados que reconocen alfa-sinucleína.
KR101438533B1 (ko) * 2012-03-30 2014-09-17 한양대학교 산학협력단 적혈구계 세포의 인 비트로 확장방법
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9303079B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
JP2015516143A (ja) 2012-04-02 2015-06-08 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ヒト疾患に関連するタンパク質の産生のための修飾ポリヌクレオチド
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
US8886625B1 (en) 2012-10-31 2014-11-11 Google Inc. Methods and computer-readable media for providing recommended entities based on a user's social graph
SMT202200337T1 (it) 2012-11-26 2022-09-14 Modernatx Inc Rna modificato al livello del terminale
US8972368B1 (en) * 2012-12-07 2015-03-03 Google Inc. Systems, methods, and computer-readable media for providing search results having contacts from a user's social graph
US10501531B2 (en) 2013-03-13 2019-12-10 Prothena Biosciences Limited Tau immunotherapy
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
US9951131B2 (en) 2013-07-12 2018-04-24 Prothena Biosciences Limited Antibodies that recognize IAPP
US9850302B2 (en) 2013-07-12 2017-12-26 Prothena Biosciences Limited Antibodies that recognize IAPP
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
WO2015051214A1 (en) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
WO2015075635A2 (en) 2013-11-19 2015-05-28 Prothena Biosciences Limited Monitoring immunotherapy of lewy body disease from constipation symptoms
KR20160131082A (ko) 2014-03-12 2016-11-15 프로테나 바이오사이언시즈 리미티드 Lg1-3에 특이적인 항-라미닌4 항체
CA2938933A1 (en) 2014-03-12 2015-09-17 Prothena Biosciences Limited Anti-laminin4 antibodies specific for lg4-5
TW201623331A (zh) 2014-03-12 2016-07-01 普羅帝納生物科學公司 抗黑色素瘤細胞黏著分子（ｍｃａｍ）抗體類及使用彼等之相關方法
US10407506B2 (en) 2014-03-12 2019-09-10 Prothena Biosciences Limited Anti-MCAM antibodies and associated methods of use
US10562973B2 (en) 2014-04-08 2020-02-18 Prothena Bioscience Limited Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
TW202204596A (zh) 2014-06-06 2022-02-01 美商健臻公司 灌注培養方法及其用途
TWI776235B (zh) * 2014-06-09 2022-09-01 美商健臻公司 種子罐培養法(seed train processes)及其用途
TWI769570B (zh) 2015-01-28 2022-07-01 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
TWI718121B (zh) 2015-01-28 2021-02-11 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
TWI786505B (zh) 2015-01-28 2022-12-11 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
WO2017046774A2 (en) 2015-09-16 2017-03-23 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
CA2998716A1 (en) 2015-09-16 2017-03-23 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
WO2017149513A1 (en) 2016-03-03 2017-09-08 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
WO2017153953A1 (en) 2016-03-09 2017-09-14 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
WO2017153955A1 (en) 2016-03-09 2017-09-14 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
SG11201809331RA (en) 2016-05-02 2018-11-29 Prothena Biosciences Ltd Antibodies recognizing tau
EA201892417A1 (ru) 2016-05-02 2019-05-31 Протена Биосайенсис Лимитед Антитела, распознающие тау
CN109415432B (zh) 2016-05-02 2022-07-08 普罗塞纳生物科学有限公司 Tau免疫疗法
WO2017208210A1 (en) 2016-06-03 2017-12-07 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
EP3478714A2 (en) 2016-07-02 2019-05-08 Prothena Biosciences Limited Anti-transthyretin antibodies
JP7016470B2 (ja) 2016-07-02 2022-02-07 プロセナ バイオサイエンシーズ リミテッド 抗トランスサイレチン抗体
WO2018007924A2 (en) 2016-07-02 2018-01-11 Prothena Biosciences Limited Anti-transthyretin antibodies
US11479798B2 (en) 2017-03-29 2022-10-25 Boehringer Ingelheim Rcv Gmbh & Co Kg Recombinant host cell with altered membrane lipid composition
MY206891A (en) 2017-05-02 2025-01-13 Prothena Biosciences Ltd Antibodies recognizing tau
WO2019064053A1 (en) 2017-09-28 2019-04-04 Prothena Biosciences Limited DOSAGE REGIMES FOR THE TREATMENT OF SYNUCLEINOPATHIES
MX2020003043A (es) 2017-10-06 2020-10-05 Prothena Biosciences Ltd Métodos para detectar transtiretina.
US20190112569A1 (en) * 2017-10-16 2019-04-18 Regeneron Pharmaceuticals, Inc. In Situ Raman Spectroscopy Systems and Methods for Controlling Process Variables in Cell Cultures
AU2018375356A1 (en) 2017-11-29 2020-05-14 Neotope Neuroscience Limited Lyophilized formulation of a monoclonal antibody against transthyretin
IL280880B2 (en) 2018-08-27 2025-04-01 Regeneron Pharma Using Raman Spectroscopy in Downstream Purification
JOP20210098A1 (ar) 2018-11-08 2023-01-30 Prothena Biosciences Ltd أجسام مضادة تتعرف على تاو
UA128431C2 (uk) 2018-11-26 2024-07-10 Форті Севен, Інк. ГУМАНІЗОВАНЕ АНТИТІЛО ДО c-Kit
TWI859197B (zh) 2019-03-03 2024-10-21 愛爾蘭商普羅帝納生物科學公司 識別ｔａｕ之抗體
CN110592044B (zh) * 2019-07-26 2021-06-22 中国农业科学院蔬菜花卉研究所 蛋白激酶Fused编码基因及其在防治小菜蛾中的应用
CN111100865B (zh) * 2020-01-07 2022-03-18 江南大学 一种提高酿酒酵母丁醇耐受能力的方法
EP4171743A4 (en) 2020-06-24 2024-07-24 Prothena Biosciences Limited Antibodies recognizing sortilin
WO2025059515A2 (en) 2023-09-15 2025-03-20 Prothena Biosciences Limited Cell penetrating agents and uses thereof
AR133828A1 (es) 2023-09-15 2025-11-05 Prothena Biosciences Ltd Anticuerpos anti-tdp-43 y sus usos
TW202528337A (zh) 2023-09-15 2025-07-16 愛爾蘭商普羅希那平台科技有限公司 包括細胞穿透藥劑之方法、組合物、及套組
TW202530246A (zh) 2023-09-15 2025-08-01 愛爾蘭商歐賽爾普羅希那有限公司 細胞穿透劑及其用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521297A (en) * 1993-06-04 1996-05-28 Salk Institute Biotechnology/Industrial Associates Nucleic acids encoding human metabotropic glutamate receptors
US5869250A (en) * 1996-12-02 1999-02-09 The University Of North Carolina At Chapel Hill Method for the identification of peptides that recognize specific DNA sequences
ATE316577T1 (de) * 1999-02-24 2006-02-15 Juan Saus Das goodpasture-antigen bindende protein
EP1067182A3 (en) * 1999-07-08 2001-11-21 Helix Research Institute Secretory protein or membrane protein
US6972324B2 (en) 2001-05-18 2005-12-06 Boehringer Ingelheim Pharmaceuticals, Inc. Antibodies specific for CD44v6
CN1511040A (zh) * 2001-05-25 2004-07-07 ����˹���ѷ��ѧ 作为多种治疗模式基础的蛋白质的选择性剪接形式
EP1560931B1 (en) 2002-11-14 2011-07-27 Dharmacon, Inc. Functional and hyperfunctional sirna
US7326768B2 (en) * 2003-02-05 2008-02-05 Juan Saus Goodpasture antigen-binding protein isoforms and protein misfolded-mediated disorders
AU2004248165A1 (en) 2003-06-11 2004-12-23 Biogen Idec Ma Inc. Method to increase protein production in culture
US7244616B2 (en) * 2003-06-27 2007-07-17 Bayer Pharmaceuticals Corporation Use of molecular chaperones for the enhanced production of secreted, recombinant proteins in mammalian cells
JP2005035926A (ja) 2003-07-14 2005-02-10 Japan Science & Technology Agency セラミド輸送を促進する薬剤、該薬剤を製造する塩基配列、セラミド遊離を促進する活性の測定方法、及びセラミドの膜間移動を促進する活性の測定方法
JPWO2005116204A1 (ja) 2004-05-11 2008-06-19 株式会社アルファジェン Ｒｎａ干渉を生じさせるポリヌクレオチド、および、これを用いた遺伝子発現抑制方法
US7989595B2 (en) * 2005-06-20 2011-08-02 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US20090018099A1 (en) 2007-03-02 2009-01-15 Hitto Kaufmann Protein production
WO2008107388A1 (en) * 2007-03-02 2008-09-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Improvement of protein production
US9340592B2 (en) * 2009-05-05 2016-05-17 Boehringer Ingelheim International Gmbh CHO/CERT cell lines

Also Published As

Publication number Publication date
MY148472A (en) 2013-04-30
US20130196430A1 (en) 2013-08-01
JP5467415B2 (ja) 2014-04-09
SI2126093T1 (sl) 2013-01-31
ES2397274T3 (es) 2013-03-05
EP2522729A1 (en) 2012-11-14
SG182160A1 (en) 2012-07-30
US20130177919A1 (en) 2013-07-11
TWI419902B (zh) 2013-12-21
NZ580043A (en) 2012-04-27
US8221999B2 (en) 2012-07-17
EA200901168A1 (ru) 2010-06-30
CA2677925A1 (en) 2008-09-12
JP2010519917A (ja) 2010-06-10
KR20100015363A (ko) 2010-02-12
TW200846368A (en) 2008-12-01
EP2126093B1 (en) 2012-10-10
HRP20121077T1 (hr) 2013-01-31
EP2522730A1 (en) 2012-11-14
EA018190B1 (ru) 2013-06-28
EP2126093A1 (en) 2009-12-02
AR065573A1 (es) 2009-06-17
PT2126093E (pt) 2012-12-03
AR086476A2 (es) 2013-12-18
CY1113710T1 (el) 2016-06-22
HK1136314A1 (zh) 2010-06-25
WO2008107388A1 (en) 2008-09-12
DK2126093T3 (da) 2013-01-07
US20080300207A1 (en) 2008-12-04
PL2126093T3 (pl) 2013-03-29
AU2008223874B2 (en) 2014-06-26
AU2008223874A1 (en) 2008-09-12
US20130197196A1 (en) 2013-08-01
BRPI0808542A2 (pt) 2014-08-26
IL200030A0 (en) 2011-08-01

Similar Documents

Publication Publication Date Title
MX2009009156A (es) Mejora de la produccion de proteina.
Poston et al. In-depth proteomic analysis of mammalian mitochondria-associated membranes (MAM)
Zhang et al. Biosynthesis and roles of phospholipids in mitochondrial fusion, division and mitophagy
AR066239A1 (es) Metodo para la produccion de proteinas mediante celulas cultivadas
BR112022011904A2 (pt) Produção de oligossacarídeo sialilado em células hospedeiras
ECSP088799A (es) Composiciones que comprenden células madre embrionarias humanas y sus derivados, métodos de uso y métodos de preparación
BR112012033699A2 (pt) polipeptídeo tendo atividade beta-glicosidase e seus usos
BR112012007854A2 (pt) metodos de produção de glicoproteínas em culturas de células de mamíferos usando glicocorticoides
BRPI0808600A2 (pt) "método para a conversão de acetolactato em dihidroxi-isovalerato, método para a produção de isobutanol, célula hospedeira recombinante e método para a identificação e isolameno de uma construção genética"
BR112022000394A2 (pt) Produção de fucosilactose em células hospedeiras
BR112014020636A2 (pt) processo biotecnológico para produção de butanol e ácido butírico
BRPI0924899B8 (pt) Síntese hmo
BR112012033404A2 (pt) polipetídeo tendo ou auxiliando a atividade de degradação de material de carboidratos e uso dos mesmos.
ECSP11011079A (es) Nuevos compuestos de hidroxiareno.
ECSP11011056A (es) Composiciones probioticas a base de grano
BR112014004543A2 (pt) método de síntese de proteínas
BR112014018610A2 (pt) alfa-amilase
UY32240A (es) Nuevas 2,4-diaminopirimidinas, sus sales farmacéuticamente aceptables, composiciones conteniéndolas y aplicaciones.
BRPI0907629A2 (pt) enzimas e genes transportadores de açúcar termoacidofílico e termofílico de alicyclobacillus acidocaldarius e organismos relacionados e métodos
BR112012033714A2 (pt) polipeptídeo com atividade de acetil xilano esterase e seus usos.
ES2560430T3 (es) Sistema de expresión en levadura para la producción de moléculas aromáticas
BR112012014683A2 (pt) processo para a produção de derivados de ácido 1-alquil/1-aril-5-pirazolcarboxílico
BR112015005416A2 (pt) produção de ácidos orgânicos por meio de fermentação em baixo ph
BRPI0606115A2 (pt) processos para a preparação de compostos éteres de pirazol [3,4-d] pirimidina
Lin et al. Effect of the myosin light chain kinase inhibitor ML-7 on the proteome of hearts subjected to ischemia–reperfusion injury

Legal Events

Date Code Title Description
FG Grant or registration